Press releases

Immunology

Johnson & Johnson strengthens pipeline to lead in atopic dermatitis with acquisition of Yellow Jersey Therapeutics

NM26 is a Phase 2-ready, first-in-class bispecific antibody targeting two clinically proven pathways in atopic dermatitis (AD)

The Company is leveraging a multi-pathway approach to transform treatment in atopic dermatitis and other immune-mediated diseases

July 11, 2024

United States

Immunology

Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis

The Company¹ enters agreement with Numab Therapeutics to acquire its wholly owned subsidiary² for the global rights to NM26, a Phase 2-ready investigational, first-in-class bispecific antibody targeting two clinically proven pathways in atopic dermatitis (AD)

NM26 has the potential to offer distinctive benefits versus existing treatments and address key unmet needs for AD patientsJ

ohnson & Johnson is committed to developing differentiated bispecific antibodies for treating AD and other immune-mediated diseases

May 28, 2024

Immunology

Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment

Acquisition advances Johnson & Johnson’s leading Dermatology portfolio with opportunity to address significant unmet need in atopic dermatitis (AD)

Includes bispecific antibodies targeting proven disease pathways and offers the potential to provide best-in-disease therapeutics for people with moderate to severe AD and asthma

These pipeline additions demonstrate the Company’s strategic approach to build a portfolio of differentiated and complementary bispecifics to address multiple disease-driving pathways

May 16, 2024

Immunology

New data shows JNJ-2113, the first and only investigational targeted oral peptide, maintained skin clearance in moderate-to-severe plaque psoriasis through one year

March 9, 2024

United States

Immunology

Investigational targeted oral peptide JNJ-2113 demonstrated positive results in moderate-to-severe plaque psoriasis in Phase 2b study published in New England Journal of Medicine

February 7, 2024

United States

Immunology

TREMFYA® (guselkumab) Demonstrates Significant and Rapid Scalp Psoriasis Clearance in People of Color in New Large Phase 3b Study

January 22, 2024

United States

Latest news

Discover J&J

Medicines & therapies

Medical devices & technology

You are now leaving innovativemedicine.jnj.com

You are now leaving innovativemedicine.jnj.com

You are now leaving innovativemedicine.jnj.com

You are now leaving innovativemedicine.jnj.com

About us

You are now leaving innovativemedicine.jnj.com

Key links

Get in touch

Search Results

No Results

Recently Viewed

Latest news

You are now leaving innovativemedicine.jnj.com

You are now leaving innovativemedicine.jnj.com

You are now leaving innovativemedicine.jnj.com

You are now leaving innovativemedicine.jnj.com

You are now leaving innovativemedicine.jnj.com